Cara Therapeutics, Inc. Reports Fourth Quarter And Full Year 2014 Financial Results

... data from ongoing Phase 2 trial of I.V. CR845 in dialysis patients - - Conference call today at 4:30 p.m. ET - SHELTON, Conn., March 26, 2015 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing ...



via Shelton Newswire http://ift.tt/1Ni37ef